drugset / Trial / NCT07248865
A Phase 1 Study of CLYM116 in Normal Healthy Volunteers
RandomizedParallel-groupDouble-blindBasic science
Summary
This Phase 1, first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CLYM116 in healthy volunteers.
Timeline
- Start
- 2025-12-02
- Primary completion
- 2026-07
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CLYM116 | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.